Trial Profile

Phase I Study of T Cells Expressing an Anti-CD22 Chimeric Receptor in Children and Young Adults With B Cell Malignancies

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD22 chimeric antigen receptor T cell therapy Kecellitics Biotech (Primary)
Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Sponsors Kecellitics Biotech

Most Recent Events

13 Dec 2022 Results assessing benefits of a second Allo-HSCT after CAR-T Cell therapy presented at the 64th American Society of Hematology Annual Meeting and Exposition
20 Dec 2019 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
20 Dec 2019 Planned primary completion date changed from 1 May 2021 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com